中国肺癌杂志Issue(5)：417-423,7.DOI:10.3779/j.issn.1009-3419.2014.05.10
pIII期非小细胞肺癌中miR-155的表达与预后关系的研究
Association of MiR-155 Expression with Prognosis in Resected Stage III Non-small Cell Lung Cancer
摘要
Abstract
Background and objective Despite undergoing curative resection, the 5-year survival rate for stage III non-small cell lung cancer (NSCLC) patients is less than 25%. hTere is a need for biomarkers for prediction of survival and guiding individual therapy. MiR-155 is one of most commonly upregulated miRNAs in malignancies, and regulates multiple pro-oncogenic pathways. We aimed to investigate the prognostic impact of miR-155 in resected stage III NSCLC patients. Methods Tumor formalin-ifxed, paraffn-embedded (FFPE) from 162 resected stage III NSCLC patients were collected. Total RNA including miRNA was extracted, and qRT-PCR was used to determine the expression of miR-155. Results Spearman rank correlation test showed a positive correlation between miR-155 expression and nodal status (r=0.169, P=0.032). MiR-155 expression had a signiifcant prognostic impact in the total cohort (P<0.001), in squamous cell carcinomas (P=0.002) and in adenocarcinomas (P=0.003). In N0-1 subgroup, miR-155 expression did not have a signiifcant prognostic on overall survival in univariate analysis (P=0.319). In N2 subgroup, miR-155 had a negative prognostic effect on OS in univariate analysis (P<0.001). Cox regression analysis revealed that miR-155 expression was unfavorable prognostic factors of OS (RR=2.311, 95%CI:1.479-3.611, P<0.001). Conclusion High expression of miR-155 represents a valuable marker of poor clinical outcomes in patients with stage III NSCLC.关键词
肺肿瘤/miR-155/预后Key words
Lung neoplasms/MiR-155/Prognosis引用本文复制引用
高轶,付圣灵,江文洋,李斌峰,田义涛,付向宁..pIII期非小细胞肺癌中miR-155的表达与预后关系的研究[J].中国肺癌杂志,2014,(5):417-423,7.基金项目
本研究受湖北省卫生厅科研项目（No.JX6B06）资助 （）
